See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

3SBio Inc. (SSRX)

Q3 2009 Earnings Call

November 13, 2009 8:00 am ET

Complete Story »

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5104544 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5098308 for the full story.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference being held at the Waldorf-Astoria Hotel in New York City, New York.

 

PolyMedix, Inc. (OTC:PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

 

Ligand Pharmaceuticals Inc., (NASDAQ:LGND) and Metabasis Therapeutics, Inc. (NASDAQ:MBRX) announced they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis.

 

Geron Corporation (NASDAQ:GERN) will announce its financial results for the 2009 third quarter on Thursday, October 29, 2009, after the closing of the equity market.

 

Life Technologies Corporation (NASDAQ:LIFE) announced results for its third quarter ended September 30, 2009.

 

BioSphere Medical, Inc. (NASDAQ:BSMD) – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy –announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

 

International Stem Cell Corporation (OTC:ISCO) and Reproductive Medicine Associates of New York (RMA of New York) have show immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived.

 

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced the Company will be presenting at the Oppenheimer 20th Annual Healthcare Conference at 3:55 p.m. EST on November 3, 2009, at the Waldorf Astoria in New York City.

 

Helicos BioSciences Corporation (NASDAQ:HLCS) announced its operational, technical and scientific highlights for the quarter ended September 30, 2009.

 

PolyMedix, Inc. (OTC:PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

 

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC), a biotechnology company which is focused on the development of novel immune-based cancer therapies, announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

 

Columbia Laboratories, Inc. (Nasdaq: CBRX) announced Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Oppenheimer 20th Annual Healthcare Conference.

 

Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

 

POZEN Inc. (NASDAQ: POZN) announced the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) an immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

 

NeoPharm, Inc. (OTC:NEOL) announced it has submitted a Phase II protocol o the FDA for the study of liposome entrapped docetaxel (LE-DT), novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.

 

OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced OSI Management will present at the Oppenheimer Healthcare Conference in New York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.

 

Manhattan Scientifics (OTCBB: MHTX) and Senior Scientific, LLC announced they have begun cooperative work to commercialize Senior Scientific’s nano medicine cancer detection technology.

 

Inhibitex, Inc. (NASDAQ: INHX) announced it would host a conference call on Friday, November 6, 2009 at 9:00 a.m. EDT to review the Company’s financial results for the third quarter ended September 30, 2009 and provide an update on recent corporate developments.

 

A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems (OTC:RHHBY) in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.

 

Revolutions Medical Corporation (OTCBB:RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced CEO Ron Wheet has been featured in the popular AllPennyStocks.com Spotlight series, produced by TheNewsWire.ca.

 

Rockwell Medical (NASDAQ:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has unveiled a new corporate identity consisting of a new logo, Company name and website.

 

Unilife Medical Solutions (OTC:UNIFF) announced it has commenced the filing of international trademarks for Unifill™, which will become the market brand for its portfolio of ready-to-fill safety syringes.

 

Orexigen® Therapeutics, Inc. (Nasdaq:OREX) announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trial of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity.

 

Cytori Therapeutics, Inc., (NASDAQ:CYTX) will present and provide a webcast of its corporate presentation at the 2009 BIOCOM Investor Conference at 1:00 PM PDT on Tuesday, October 27, 2009.

 

King Pharmaceuticals, Inc. (NYSE:KG) announced it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.

 

McKesson Corporation (NYSE:MCK) reported revenues for the second quarter ended September 30, 2009 were $27.1 billion compared to $26.6 billion a year ago.

 

Please note a change to the Merge Healthcare Inc., (NASDAQ:MRGE) third quarter 2009 earnings call. The call, which was previously scheduled for 4:15 PM EDT on Thursday, October 29, 2009, will now be held at 9:00 AM EDT.

 

PPD, Inc. (Nasdaq:PPDI) reported its financial and operating results for the third quarter ended September 30, 2009.

 

Total Nutraceutical Solutions, Inc. (OTC:TNUS), announced the company has formulated and will launch a unique natural whole food mushroom-based Vitamin D supplement.

 

Osteologix, Inc. (OTC:OLGX) announced Philip J. Young, President and CEO of Osteologix, will present a corporate overview and update at the 8th Annual Bio Investor Forum being held this week at the Palace Hotel in San Francisco, California.

 

3SBio Inc. (Nasdaq:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced it will release financial results for the third quarter ended September 30, 2009 after the US market closes on Thursday, November 12, 2009.

 

 

TomoTherapy Inc., (NASDAQ:TOMO) announced four recipients of grants from the first round of its 2009-2010 TomoTherapy® Clinical Investigation Partnership Program.

 

{tiny;BIOC;3} BioClinica, Inc. (NASDAQ: BIOC) will release its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009.

Management of BioClinica, Inc. will host a conference call on the same day at 11 a.m. EST. Those who wish to participate in the conference call may telephone 888-335-6674 from the U.S.; international callers may telephone 973-321-1100, approximately 15 minutes before the call. The conference ID# for both numbers is 36541392. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 800-642-1687 from the U.S. or 706-645-9291 for international callers, conference ID# 36541392. The replay will also be on the website under “Investor Relations” at www.bioclinica.com for two weeks.

{tiny;MDVN;3} Medivation, Inc. (Nasdaq:MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2009 will be released after markets close on November 4, 2009.

Interested parties may call 877-874-1563 from the U.S. or +1-719-325-4891 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

 

{tiny;GNVC;3} GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the third quarter ended September 30, 2009 on Thursday, November 5, 2009 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, November 6, 2009 to discuss the company's third quarter results.

To listen to the live conference call, please dial 888-679-8040 (U.S. or Canada) or 617-213-4851 (international) and use access code 35178683. Participants may pre-register for the call anytime at:

https://www.theconferencingservice.com/prereg/key.process?key=PPCBK3H6R.

Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 1:00 p.m. on November 6, 2009 through November 12, 2009. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 28987203.

{tiny;RIGL;3} Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows: Oppenheimer 20th Annual Healthcare Conference Waldorf Astoria, New York City, NY November 3, 2:10 p.m. EST Speaker: Raul R. Rodriguez Credit Suisse 18th Annual Healthcare Conference Arizona Biltmore Hotel, Phoenix, AZ November 11, 2:00 p.m. MST Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

{tiny;HALO;3} Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report third quarter 2009 financial results on Friday, November 6, 2009 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST (11:00 a.m. EST), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the third quarter 2009 and provide a product pipeline update.

To participate by telephone please dial 888-256-9044 for domestic callers or 706-643-5585 for international callers and provide the conference ID # 37881291. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme’s Web site for seven days. A telephone replay will be available by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.

Halozyme management team members will also be presenting at upcoming investor conferences.

Oppenheimer 20th Annual Healthcare Conference, November 4, 2009, 3:20 p.m. EST, New York City Lazard Capital Markets 6th Annual Healthcare Conference, November 18, 2009, 11:30 a.m. EST, New York City

To listen to the audio webcast of the presentations live or after the event, please visit the company’s Web site at www.halozyme.com. Replays will be available for 30 days after the presentations.

{tiny;ZGEN;3} ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Stephen W. Zaruby, President of ZymoGenetics, will provide an update on company activities at the Oppenheimer 20th Annual Healthcare Conference in New York City on Wednesday, November 4, 2009 at 10:50 a.m. Eastern Time.

A live webcast of the presentation can be accessed by going to: www.zymogenetics.com. The webcast will be archived for 30 days.

 

 

 

{tiny;SSRX;3} 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the third quarter ended September 30, 2009 after the US market closes on Thursday, November 12, 2009.

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on Friday, November 13, 2009 to discuss its 2009 third quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 38479039 Local dial-in: China - landline 800-819-0121 China - mobile 400-620-8038 International toll-free dial-in: Hong Kong 800930346 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65-6735-7955 Replay-Conference ID: 38479039

A telephone replay will be available two hours after the call until November 20, 2009, at:

International dial-in: +61-2-8235-5000 United States dial-in: 1-866-214-5335

Webcast

A live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/yf93ntk . A replay of the webcast will be available within one hour after the conclusion of the call.

{tiny;OSIP;3} OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI Management will present at the Oppenheimer Healthcare Conference in New York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.

The presentation will be webcast live and may be accessed by visiting OSI’s website at www.osip.com. A replay of the webcast will also be available on the Company’s website until November 17, 2009.

 

 

{tiny;CPIX;3} Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will report third quarter 2009 financial results before the market opens on Tuesday, November 10, 2009.A conference call and live Internet webcast will be held on Tuesday, November 10, 2009 at 10:00 a.m. Eastern Time to discuss the results.

To participate on the call, please dial 888-417-8462 (for U.S. callers) or 719-457-2552 (for international callers).A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112 (for U.S. callers) or 719-457-0820 (for international callers).The passcode for the rebroadcast is 9695498.The live webcast and rebroadcast can be accessed via Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm.

{tiny;INHX;3} Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Friday, November 6, 2009 at 9:00 a.m. EDT to review the Company’s financial results for the third quarter ended September 30, 2009 and provide an update on recent corporate developments.

The Company will issue a press release regarding its financial results on the same day, prior to the conference call.

Webcast Information:  To access the conference call, please dial 877-407-8033 (domestic) or 201-689-8033 (international). A replay of the call will be available from 11:00 a.m. EDT on November 6 until December 6, 2009 at midnight. To access the replay, please dial 877-660-6853 (domestic) or 201-612-7415 (international) and reference the account # 286 and the conference id # 336098. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at http://www.inhibitex.com.

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index inc[More...]